NCT01099540

Brief Summary

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
37

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Apr 2010

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

April 6, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 7, 2010

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
Last Updated

December 29, 2015

Status Verified

December 1, 2015

Enrollment Period

1.9 years

First QC Date

April 6, 2010

Last Update Submit

December 28, 2015

Conditions

Neuroendocrine Tumor

Keywords

neuroendocrine tumor

Outcome Measures

Primary Outcomes (1)

  • response rate

    1~2 year

Study Arms (1)

Pazopanib

EXPERIMENTAL
Drug: Pazopanib

Interventions

PazopanibDRUG

Pazopanib 800 mg qd daily

Pazopanib

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

You may not qualify if:

  • poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Cancer Center

Seoul, South Korea

Location

Related Publications (1)

  • Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013 Sep 17;109(6):1414-9. doi: 10.1038/bjc.2013.470. Epub 2013 Aug 29.

    PMID: 23989950DERIVED

MeSH Terms

Conditions

Neuroendocrine Tumors

Interventions

pazopanib

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve Tissue

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 6, 2010

First Posted

April 7, 2010

Study Start

April 1, 2010

Primary Completion

March 1, 2012

Study Completion

March 1, 2013

Last Updated

December 29, 2015

Record last verified: 2015-12

Locations

KR(1)